Category Specific RSS

Categories: News

Neuren secures European patent for drug aimed to treat incurable brain disorders

Australian biopharmaceuticals developer Neuren Pharmaceuticals (ASX: NEU) has been granted a patent from the European Patent Office covering NNZ-2591, a world-first drug being developed to treat three neurodevelopmental disorders which affect children, and are currently incurable. 

The granting of the new patent is the third jurisdiction to do so for Neuren with the same application previously granted in the United States and Japan. Titled “Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders,” the patent will enable advancing the development of NNZ-2591 which has already delivered encouraging results when applied to mice. 

The three neurodevelopmental diseases being targeted by Neuren with NNZ-2591 are Phelen-McDermaid syndrome, Angelman syndrome and Pitt Hopkins syndrome which share underlying impairment of signalling between brain cells. 

All three developmental diseases impact the development of a child’s brain which lead to varying levels of intellectual disability and are caused by gene mutations and deletion. 

Because the three diseases are so rare, Neuren has been granted Orphan Drug designation from the United States Food & Drug Administration (FDA) which provides Government assistance to drug research for diseases so rare that there would otherwise be no commercial value to conduct the research. 

Neuren is currently undertaking the non-clinical studies for NNZ-2591 but anticipate submitting an FDA application to commence clinical trials in 2020. 

Beyond the development of NNZ-2591, Neuron is currently undertaking Phase 3 clinical trials for its trofinetide product aimed at treating Rett syndrome, another rare neurological disorder which the Company has attained FDA Orphan Drug and Fast Track designation for. 

Alfred Chan

Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.

Recent Posts

Biotron Expands into Anaesthetics with Sedarex Acquisition and $2.5m Raise

Biotech company Biotron Limited (ASX:BIT) has announced a bold step into the anaesthetics sector, acquiring…

4 days ago

DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment

DroneShield (ASX:DRO) is expanding its Australian footprint with a $13 million investment to establish a…

2 weeks ago

Stakk Secures T-Mobile Contract to Power Super App Expansion

Australian fintech Stakk (ASX:SKK) has signed a three-year agreement with U.S. telecommunications giant T-Mobile USA,…

3 weeks ago

Medibank Backs Emyria with Landmark Depression Care Deal

Australia’s mental health burden is growing – and one of the toughest challenges is treatment-resistant…

4 weeks ago

NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI

NoviqTech Limited (ASX:NVQ) has taken a decisive step into the quantum computing market, unveiling the…

1 month ago

BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil

Brazilian Rare Earths Limited (ASX:BRE) has cleared its last regulatory hurdle to begin pilot operations…

2 months ago